Background
==========

Incident use of central venous catheters (CVCs) as initial hemodialysis (HD) access is associated with increased mortality in prospective studies and large registry analyses \[[@B1]-[@B4]\]. While CVCs are more common in late referrals \[[@B5]\], they are associated with a higher mortality risk compared to arteriovenous fistulas (AVFs) even after adjusting for timing of referral \[[@B1]\]. Dialysis with a CVC is also associated with a higher risk of death compared to peritoneal dialysis (PD) \[[@B6]\]. As a result of the association between CVCs and mortality in HD, guidelines recommend the use of an AVF as initial HD access \[[@B7]-[@B9]\]. Recognizing that AVFs require time to mature, guidelines also suggests that AVF creation should occur in a timely fashion. Timely initiation of PD in patients with chronic kidney disease (CKD) is also emphasized \[[@B10]\]. Despite these recommendations, most incident patients continue to dialyze with a CVC \[[@B2],[@B6]\].

With a few exceptions \[[@B11],[@B12]\], CVCs are used as initial dialysis access in patients with acute renal failure/acute kidney injury (AKI) or acute on early stage chronic kidney disease (ACKD), as timely placement of alternative access is not a consideration in these patients. As high as 16 % and 28 % of patients do not recover kidney function after acute renal failure \[[@B13]\] and ACKD \[[@B14]\], respectively. In addition, progression to end stage renal disease (ESRD) in both these situations is itself associated with increased mortality \[[@B13],[@B14]\].

A previous cohort study identified that an "emergency dialysis start" confounded the association between CVCs and mortality \[[@B15]\]. However, this study did not separately analyze patients with an acute decline in GFR from patients presenting emergently with late stage CKD. A recent case series identified that a rapid decline in estimated glomerular filtration rate (eGFR; in patients with an eGFR \>30 ml/min/1.73 m^2^) may be an unavoidable cause of incident use of CVCs, but did not examine its association with mortality \[[@B16]\].

Therefore, in a retrospective cohort of incident dialysis patients, the purposes of this study were to explore the following:

1\) Determine the proportion of incident dialysis patients who develop ESRD after a permanent loss of GFR in the context of an acute illness event ("acute start").

2\) Identify if patients who start dialysis under this circumstance are at an increased risk of mortality.

3\) Determine if CVCs are associated with mortality, and if this association persists after excluding patients with an illness induced permanent GFR loss.

We hypothesize that CVC mortality may be overestimated without considering the influence of an acute start.

Methods
=======

Population
----------

We conducted a retrospective cohort study consisting of 481 consecutive, adult (\> 18 years) ESRD dialysis starts at a tertiary care center in Halifax, Nova Scotia, Canada over a period of 48 months (1 Jan 2006 to 31 Dec 2009). We chose this time frame to coincide with the availability of electronic patient/ESRD database records at our institution (which commenced just prior to Jan 2006), and ensure a minimum of one year of follow-up from the last date of study entry. Patients were excluded if they transferred to another regional dialysis unit (Prince Edward Island, Cape Breton or Yarmouth) or out of province after having received only their initial HD in Halifax.

Exposure assessment
-------------------

Patients were classified as "acute start" under the following circumstances:

1\) eGFR by MDRD \>25 ml/min/1.73 m^2^ ≤ three months prior to dialysis initiation that declined in the context of an acute illness event requiring hospitalization.

2\) Acute illness event leading to dialysis initiation in patients without prior eGFR measurements and no suggestion of chronic kidney disease on history or renal ultrasound \[[@B16]\].

Remaining patients were classified as "chronic start":

1\) eGFR by MDRD ≤25 ml/min/1.73 m^2^ \> three months prior to dialysis initiation.

2\) eGFR by MDRD \>25 ml/min/1.73 m^2^ ≤ three months prior to dialysis initiation without a documented acute illness event.

3\) Late presentation of ESRD, suggested by ultrasound evidence of bilateral small kidneys in individuals without prior eGFR measurements \[[@B17]\].

The definition of an acute start was made on the assumption that most patients are not referred for evaluation and/or placement of AVF or PD catheter access prior to reaching an eGFR of \<25 ml/min/1.73 m^2^. This is consistent with previously published guideline recommendations on appropriate referral for permanent access placement \[[@B7],[@B9]\]. Therefore, we expected that the vast majority of patients with an eGFR of \>25 ml/min/1.73 m^2^ who progressed to ESRD within three months would be unexpected dialysis starts without established or planned alternative access.

Access at dialysis initiation was classified as a central venous catheter (CVC), peritoneal dialysis (PD) catheter or arteriovenous fistula (AVF). There was only one arteriovenous graft at this center and for the purpose of this study it was classified as a fistula. AVF access required completion of one dialysis treatment with the AVF. PD access required successful completion of the training program. No incident patients were on combination therapy. All patient definitions were independently assessed by a nephrologist and nephrology fellow, subsequent to which consensus was achieved.

Baseline data
-------------

Clinical data, including cause and date of death was accessed from individual patient Canadian Organ Replacement Registry (CORR) forms and supplemented with electronic patient record data. In addition to cause of ESRD, date of dialysis initiation and access type, a Charlson Comorbidity Index (CCI) was calculated at the time of dialysis start in all incident patients. This index allocates different point scores to 19 individual medical conditions depending on the risk of mortality associated with each condition \[[@B18]\]. We also collected several laboratory parameters including creatinine, phosphate, hemoglobin and albumin in all patients at baseline. All assays were performed by the institution's laboratory. We manually calculated a four variable modified diet in renal disease (MDRD) eGFR at dialysis initiation in all patients, using available creatinine measurements. In addition, we used electronic chart and laboratory systems review to identify available outpatient creatinine values (from which we calculated eGFRs) at 1, 3, 6, 9 and 12 months prior to dialysis initiation. We allowed a ± two-week time frame at each time interval. Finally, the acute event prompting dialysis initiation in acute start patients was determined using electronic patient records.

Outcome
-------

We initially examined the time to all cause mortality from dialysis initiation for acute vs. chronic start patients and for CVC vs. PD/AVF access. After excluding acute start patients, the primary outcome of this study was to analyze the time to death for CVC vs. PD/AVF access. Patient survival was censored at transplantation or date of last follow-up (31 Mar 2011).

Statistical analysis
--------------------

Results were reported as counts and percentages for categorical variables, mean ± standard deviation for normally distributed continuous variables and median and interquartile range for non-normally distributed continuous variables. Categorical variables were compared using the Fisher's Exact Test. Continuous variables were compared with t-tests and the Wilcoxon Rank Sum Test for normally and non-normally distributed variables, respectively. In addition, we performed an analysis of baseline characteristics restricted to chronic start patients, using the same statistical methods outlined above. Missing laboratory data was addressed using regression mean imputation. Complete variables chosen to impute missing data were age, gender, CCI and referral days. The time to mortality was graphed using the Kaplan-Meier product limit method and adjusted Cox survival curves. Adjusted hazard ratios and 95 % confidence intervals (CI) were estimated from multivariable Cox proportional hazards models. Variables selected for inclusion in the models were based on clinical judgment and known predictors derived from the literature. These variables included age, CCI, ESRD due to diabetes, gender, referral time, albumin, hemoglobin, phosphate and eGFR \[[@B19]-[@B26]\]. Interactions were examined for all variables used in the Cox survival analysis. Proportionality was examined with the test based on scaled Schoenfeld residuals. In addition to the primary analysis, we performed sensitivity analyses without censoring at transplantation, and using an eGFR cut-off of 30 ml/min/1.73 m^2^. All statistical analyses were performed using STATA IC, version 12 (StataCorp, College Station, TX). A two-sided P value \< 0.05 was considered statistically significant. This study was approved by the Queen Elizabeth II Health Sciences Centre research ethics board, our institutional research ethics committee.

Results
=======

All patients
------------

After exclusions (Figure [1](#F1){ref-type="fig"}), 406 patients were followed for a median of 22 months (IQR 13 to 35 months). 57 and 349 patients met the criteria for acute and chronic start, respectively. Amongst the chronic start patients, 335 fulfilled the definition based on eGFR criteria. One patient had an eGFR \> 25 ml/min/1.73 m^2^ within three months of dialysis initiation, but without an acute illness event. The remaining 14 chronic start patients did not have eGFRs available between 12 and 3 months prior to starting dialysis, but small kidneys on ultrasound suggesting preexisting chronic kidney disease. Baseline characteristics of both groups are noted in Table [1](#T1){ref-type="table"}. 36/57 and 9/57 acute start patients (63 % and 16 %) had eGFR measurements available at three and one month prior to dialysis initiation. The mean eGFR of these groups was 44 and 50 ml/min/1.73 m^2^, respectively. Of the remaining 12 patients without prior eGFR measurements, 8 had rapidly progressive glomerulonephritis (RPGN), 3 had multiple myeloma and 1 had pneumonia. The acute events leading to dialysis initiation in all acute start patients are noted in Figure [2](#F2){ref-type="fig"}.

![Cohort selection.](1471-2369-13-72-1){#F1}

###### 

Baseline characteristics of acute and chronic start patients

                                                             **Acute Start (n = 57)**   **Chronic Start (n = 349)**   **P**
  ---------------------------------------------------------- -------------------------- ----------------------------- ---------
  Age at dialysis start, years, (mean ± SD)                  71 ± 12.0                  62 ± 16                       \<0.001
  Male gender, n (%)                                         32 (57)                    202 (58)                      0.89
  Caucasian race, n (%)                                      50 (88)                    323 (93)                      0.20
  **Dialysis Access, n (%)**                                                                                          
  CVC                                                        56 (98)                    182 (52)                      \<0.001
  AVF                                                        1 (2)                      95 (27)                       \<0.001
  PD catheter                                                0                          72 (21)                       \<0.001
  **Cause of ESRD, n (%)**                                                                                            
  Diabetes                                                   8 (14)                     110 (32)                      0.007
  Polycystic kidney disease                                  2 (4)                      30 (9)                        0.29
  Glomerulonephritis                                         10 (18)                    44 (13)                       0.53
  Referral time before dialysis start, days, (median, IQR)   3, 1 to 33                 1087, 443 to 2571             \<0.001
  Referral \< 3 months, n (%)                                47 (82)                    34 (10)                       \<0.001
  **Comorbidity**                                                                                                     
  CCI (median, IQR)                                          5, 3 to 7                  4, 2 to 6                     0.03
  Diabetes, n (%)                                            23 (41)                    154 (44)                      0.38
  Coronary artery disease, n (%)                             15 (27)                    100 (29)                      0.73
  Congestive heart failure, n (%)                            17 (30)                    77 (22)                       0.18
  Peripheral vascular disease n (%)                          14 (25)                    78 (22)                       0.73
  Malignancy^a^, n (%)                                       17 (30)                    34 (10)                       \<0.001
  **Laboratory Values**                                                                                               
  Hemoglobin, g/L, (mean ± SD)                               93 ± 15                    100 ± 17                      0.004
  Albumin, g/L, (median, IQR)                                26, 23 to 30               33, 28 to 36                  \<0.001
  Phosphate, mmol/L, (median, IQR)                           1.9, 1.4 to 2.6            1.8, 1.5 to 2.2               0.33
  Imputed phosphate^b^                                       1.9, 1.5 to 2.6            1.9, 1.5 to 2.6               0.26
  eGFR, ml/min/1.73 m^2^, (median, IQR)                      6.8, 5.0 to 9.0            7.8, 6.0 to 10                0.01
  Imputed eGFR^c^                                            6.8, 5.0 to 9.0            7.8, 6.0 to 10                0.01

a: Including hematologic or non-hematologic, excluding non-melanoma skin cancer.

b: 31 missing values imputed.

c: 3 missing values imputed.

![**Acute illness event leading to dialysis initiation.** Causes for category "other" were as follows: toxic acute tubular necrosis (ATN), atheroemboli, hypovolemic ischemic ATN, scleroderma renal crisis, tumour lysis syndrome (1 for each).](1471-2369-13-72-2){#F2}

At last follow up, there were 62 kidney transplants and 148 deaths. 4/38 acute and 2/110 chronic start deaths were attributed to catheter-related sepsis (11 % and 2 % respectively). Causes of death are noted in Table [2](#T2){ref-type="table"}. The two chronic start patients that died of catheter-related sepsis were 68 and 86 years of age. The first had a failed attempt at fistula creation prior to dialysis, and the latter chose PD but had an absolute contraindication due to a lack of home support and dementia. One additional chronic start patient (86 years of age), died from complications related to the CVC (superior vena cava thrombosis). This patient refused fistula creation prior to dialysis initiation. In the fully adjusted Cox model, an acute dialysis start was associated with shorter time to mortality compared to a chronic start (HR 1.84, 95 % CI \[1.19-2.85\], Table [3](#T3){ref-type="table"}). Kaplan Meier survival curves for acute and chronic start patients are noted in Figure [3](#F3){ref-type="fig"}.

###### 

Cause of death for acute and chronic start patients

  **Cause**                                                                       **Acute Start (n = 38)**   **Chronic Start (n = 110)**
  ------------------------------------------------------------------------------- -------------------------- -----------------------------
  Catheter-related sepsis                                                         4                          2
  Sepsis: other source                                                            7                          10
  Cardiac (valvular, arrest, congestive heart failure, acute coronary syndrome)   7                          30
  Neurologic (stroke, seizure, delirium, demyelinating, dementia)                 6                          11
  Non myeloma cancer                                                                                         9
  Multiple myeloma                                                                3                          1
  Withdrawal due to quality of life                                               5                          20
  Gastrointestinal illness (bleed, obstruction)                                   3                          3
  Unknown                                                                         2                          16
  Respiratory failure                                                                                        2
  Other                                                                           1^a^                       6^b^

a: Drug reaction.

b: Cirrhosis, failed bone marrow transplant, suicide, calciphylaxis, refractory hypotension, superior vena cava thrombosis.

###### 

Cox survival analysis for acute vs. chronic start patients

  **Model**    **HR \[95 % CI\]**      **P**
  ------------ ----------------------- ---------
  Unadjusted   2.83 \[1.95 to 4.09\]   \<0.001
  Model 1^a^   2.56 \[1.76 to 3.71\]   \<0.001
  Model 2^b^   2.35 \[1.59 to 3.47\]   \<0.001
  Model 3^c^   2.14 \[1.42 to 3.22\]   \<0.001
  Model 4^d^   1.84 \[1.19 to 2.85\]   0.006

a: Adjusted for age and gender.

b: Adjusted for factors in a. CCI and ESRD due to diabetes.

c: Adjusted for factors in b. and referral days.

d: Adjusted for factors in c. hemoglobin, albumin, phosphate and eGFR.

![Kaplan Meier survival curves for acute and chronic start patients.](1471-2369-13-72-3){#F3}

CVC associated mortality
------------------------

In the fully adjusted Cox model, the mortality HR for CVC vs. PD/AVF access was 1.19 (95 % CI, \[0.80-1.77\]). After excluding all acute starts, 349 chronic start patients remained for further analysis. Of these patients, 182 (52 %) initiated dialysis with a CVC. Baseline characteristics of patients dialyzing with a CVC vs. alternative access (PD catheter or AVF) are noted in Table [4](#T4){ref-type="table"}. In the fully adjusted Cox model for chronic dialysis start patients, the mortality HR for CVCs vs. PD/AVF access was 1.03 (95 % CI \[0.67 to 1.57\], Table [5](#T5){ref-type="table"}). Adjusted Cox survival curves for CVC vs. PD catheter/AVF access in the complete and restricted cohort are noted in Figure [4](#F4){ref-type="fig"}.

###### 

Baseline characteristics of chronic start dialysis patients stratified by access

  **Variable**                                               **CVC access (n = 182)**   **PD or fistula access (n = 167)**   **P**
  ---------------------------------------------------------- -------------------------- ------------------------------------ ---------
  Age at dialysis start, years, (mean ± SD)                  62 ± 16.0                  62 ± 16                              0.95
  Male gender, n (%)                                         96 (53)                    106 (63)                             0.05
  Caucasian race, n (%)                                      166 (91)                   157 (94)                             0.42
  **Dialysis Access, n (%)**                                                                                                 
  CVC                                                        56 (98)                    182 (52)                             \<0.001
  AVF                                                        1 (2)                      95 (27)                              \<0.001
  PD catheter                                                0                          72 (21)                              \<0.001
  **Cause of ESRD, n (%)**                                                                                                   
  Diabetes                                                   64 (35)                    46 (28)                              0.14
  Polycystic kidney disease                                  9 (5)                      21 (13)                              0.01
  Glomerulonephritis                                         23 (13)                    22 (13)                              1.00
  Referral time before dialysis start, days, (median, IQR)   734, 196 to 1966           1623, 687 to 3115                    \<0.001
  Referral \< 3 months, n (%)                                32 (18)                    2 (1)                                \<0.001
  **Comorbidity**                                                                                                            
  CCI (median, IQR)                                          5, 3 to 7                  3, 2 to 6                            \<0.001
  Diabetes, n (%)                                            91 (50)                    63 (38)                              0.02
  Coronary artery disease, n (%)                             62 (34)                    38 (23)                              0.02
  Congestive heart failure, n (%)                            44 (24)                    33 (20)                              0.37
  Peripheral vascular disease n (%)                          54 (30)                    24 (14)                              0.001
  Malignancy^a^, n (%)                                       23 (13)                    11 (7)                               0.07
  **Laboratory Values**                                                                                                      
  Hemoglobin, g/L, (mean ± SD)                               96 ± 17                    105 ± 17                             \<0.001
  Albumin, g/L, (median, IQR)                                31, 25 to 34               34, 31 to 38                         \<0.001
  Phosphate, mmol/L, (median, IQR)                           1.8, 1.5 to 2.3            1.8, 1.5 to 2.2                      0.19
  Imputed phosphate^b^                                       1.9, 1.6 to 2.3            1.8, 1.5 to 2.1                      0.13
  eGFR, ml/min/1.73 m^2^, (median, IQR)                      7.2, 5.8 to 9.7            8.1, 6.2 to 10.9                     0.01
  Imputed eGFR^c^                                            7.3, 5.8 to 9.6            8.1, 6.2 to 10.9                     0.01

a: Including hematologic or non-hematologic, excluding non-melanoma skin CA.

b: 21 missing values imputed.

c: 3 missing values imputed.

###### 

Cox survival analysis for CVC vs. AVF/PD catheter access

  **Model**                                                                                 **HR \[95 % CI\]**      **P**
  ----------------------------------------------------------------------------------------- ----------------------- -------
  **Complete cohort (n = 406)**                                                                                     
  Unadjusted                                                                                1.70 \[1.20 to 2.41\]   0.003
  Model 1^a^                                                                                1.73 \[1.22 to 2.45\]   0.002
  Model 2^b^                                                                                1.55 \[1.08 to 2.22\]   0.02
  Model 3^c^                                                                                1.41 \[0.97 to 2.05\]   0.07
  Model 4^d^                                                                                1.19 \[0.80 to 1.77\]   0.40
  Model 4^d^ without censoring at transplantation                                           1.16 \[0.78 to 1.73\]   0.45
  **Excluding acute start patients (n = 349)**                                                                      
  Unadjusted                                                                                1.36 \[0.93 to 2.00\]   0.11
  Model 1^a^                                                                                1.42 \[0.97 to 2.09\]   0.07
  Model 2^b^                                                                                1.28 \[0.87 to 1.90\]   0.21
  Model 3^c^                                                                                1.23 \[0.83 to 1.84\]   0.30
  Model 4^d^                                                                                1.03 \[0.67 to 1.57\]   0.91
  Model 4^d^ without censoring at transplantation                                           0.99 \[0.64 to 1.51\]   0.95
  **Excluding acute start patients with an eGFR \> 30 ml/min/1.73 m**^**2**^**(n = 359)**                           
  Unadjusted                                                                                1.42 \[0.97 to 2.06\]   0.07
  Model 1^a^                                                                                1.46 \[1.00 to 2.13\]   0.05
  Model 2^b^                                                                                1.32 \[0.89 to 1.94\]   0.16
  Model 3^c^                                                                                1.26 \[0.85 to 1.87\]   0.24
  Model 4^d^                                                                                1.05 \[0.69 to 1.61\]   0.81
  Model 4^d^ without censoring at transplantation                                           1.02 \[0.67 to 1.55\]   0.94

a: Adjusted for age and gender.

b: Adjusted for factors in a. CCI and ESRD due to diabetes.

c: Adjusted for factors in b. and referral days.

d: Adjusted for factors in c. hemoglobin, albumin, phosphate and eGFR.

![Adjusted Cox survival curves for CVC vs. PD catheter/AVF access in A) all patients and B) chronic start patients.](1471-2369-13-72-4){#F4}

Discussion
==========

In this single center study of consecutive incident dialysis patients, we identified that a proportion of patients with a normal eGFR or early stage CKD (1 to early stage 4), initiated dialysis after an illness that induced a permanent, rapid loss of eGFR. Virtually all of these patients used a CVC as initial dialysis access. While this acute start patient group made up only a small percentage of all dialysis starts, they were at an increased risk for mortality compared to chronic start patients. Finally, CVCs were associated with a trend to increased mortality, but amongst chronic dialysis starts, the mortality risk of CVCs was attenuated and comparable to patients with alternative access.

For the chronic start patients, there are potential reasons that dialysis access was not associated with increased mortality, a finding in contrast to large registry studies \[[@B2],[@B6]\]. An association between mortality and AKI/ACKD leading to ESRD has been demonstrated in previous studies \[[@B13],[@B14],[@B27]\]. The majority of these patients initiate dialysis with a CVC. However, even patients with non-dialysis requiring AKI have a higher mortality risk compared to those without AKI \[[@B28]\]. This emphasizes that the association between CVC access and mortality (in AKI patients who do not recover kidney function) may be the result of AKI itself. Alternatively AKI or ACKD may negatively impact on other factors that have been known to influence mortality in dialysis patients, such as residual renal function \[[@B29],[@B30]\]. If these patients are not excluded from studies of incident dialysis and mortality, the mortality risk of CVCs may be overestimated. Another consideration is that the comparable survival for CVC vs. AVF/PD catheter access after exclusion of acute starts may be related to access conversion. While it was not the intention of this study, it has been shown that conversion from a CVC to an AVF after dialysis initiation is associated with increased survival \[[@B31]\].

The suggestion that the CVC associated mortality may be overestimated is further supported in our analysis of cause of death. Only 7/148 patient deaths (5 %) were clearly a direct result of the CVC itself (infection or vascular thrombosis). 4 of the 7 patient deaths were acute starts, a population who may be at an increased risk of hospital acquired bacteremia from other sources. While cause of death may have been subject to classification error, we were able to corroborate data with electronic records in this study. In contrast, registry studies may not always have access to individual records to confirm or refute cause of death \[[@B32]\].

However, even if CVC related mortality was underestimated in this study, complete avoidance of CVCs may be unrealistic and unachievable for a large number of incident dialysis patients. The three chronic start patients who died of catheter sepsis had largely unavoidable reasons for CVC use including previous access failure and patient refusal of alternative access. Furthermore, a recent study determined that the majority of late referred ESRD dialysis starts are unavoidable \[[@B33]\], and it can be assumed that many of these patients start dialysis with a CVC. This assumption was confirmed in our study, namely, that a sizeable proportion of patients develop ESRD after a rapid loss of eGFR, a setting in which alternative access is not anticipated. The notion that CVCs should be avoided at all costs also needs to be reconsidered in light of AVF success rates. Fistulas continue to have a high primary non-function rate \[[@B34]-[@B36]\]. The utility of AVFs is also questioned in many older patients. This is in part due to the high competing risk of death prior to dialysis access and the significant early mortality risk of elderly CKD patients with functioning access after the start of dialysis \[[@B37],[@B38]\]. Overall, these scenarios suggest that while AVF and PD catheter access are preferred, there will still be considerable numbers of dialysis starts that will not be optimal despite our best efforts \[[@B39],[@B40]\].

The findings of our study need to be compared to other cohort studies examining the association between dialysis access, acute start and mortality. The findings in our study were similar to a recent analysis of Veterans Affairs (VA) patients in which a "catastrophic loss of eGFR" (defined as loss from levels \>60 ml/min/1.73 m^2^ within 6 months or less) was associated with early mortality \[[@B41]\]. While those patients initiated dialysis at a higher eGFR than our study (in part because the definition of predialysis eGFR was different), both studies highlight the importance of a rapid eGFR decline and its impact on mortality. In a large French REIN registry analysis of incident dialysis patients with congestive heart failure (CHF), despite excluding unplanned dialysis starts, CVC use was still associated with a statistically significant mortality HR of 1.35 (95 % CI 1.22-1.49) \[[@B42]\]. However, unlike the REIN study, our cohort had both CHF and non-CHF patients. In addition, the definition of an acute start differs from the unplanned definition used in REIN cohort studies \[[@B42],[@B43]\]. We only classified AKI/ACKD patients who started dialysis as "acute starts", but not those with previously undiagnosed or uninvestigated late stage CKD who presented late. While speculative, the latter may be a group of "survivors" (by virtue of being able to survive to the point of getting dialysis access) that would have been excluded from the REIN chronic cohort of planned dialysis starts.

There are limitations to this study. Three-month eGFR measurements were not available in all patients and ultrasound or patient history may be inaccurate in differentiating acute and chronic kidney disease. However, using the criteria in our definition, and considering the acute events in this patient group (primarily RPGN and myeloma) it was not illogical to classify patients as an acute start when eGFRs were not readily available. While the accuracy of our ESRD database is enhanced by its use of detailed electronic records, we acknowledge that there may have been some patients with AKI and early mortality that were misclassified as ESRD patients, or ESRD acute starts that were not included in this study. Because of a lack of frequent eGFR measurements in all patients, it was not possible to accurately capture the rate of eGFR decline and incorporate it into the definition. Some authorities may advocate for placement of a fistula or PD catheter at an eGFR \>25 ml/min/1.73 m^2^ if a patient were experiencing a rapid decline in eGFR. However, a sensitivity analysis using a more conservative eGFR cutoff of \>30 ml/min/1.73 m^2^ (corresponding to the lower limit of stage 3 CKD), did not change the results of our study. A final limitation of our definition of acute start is that fistulas or PD catheters can be placed and accessed within 3 months of identifying a need for dialysis. However, our population also required an acute illness event to precipitate the decline in eGFR prior to dialysis initiation. Therefore, most physicians would be unprepared to institute optimal access placement in this population. This would be true for patients with a recent cardiac/septic event or admission in an individual with potentially reversible AKI (i.e. myeloma or RPGN). In addition to the study population, there are other limitations inherent to the study design. Despite controlling for multiple variables, there is the possibility of residual confounding and bias. It is possible that a larger study may detect a small, persistent, residual early mortality risk associated with CVCs. Furthermore, while we attempted to capture all of the CVC related deaths, 15 % of deaths amongst chronic start patients were of unknown cause. It is possible that additional catheter-related septic deaths were missed in this group.

It should be emphasized that while this study suggests that the mortality attributed to CVCs needs to be examined after consideration of an "acute start", we are not suggesting that CVCs are optimal dialysis access. We acknowledge that our patients may have developed CVC complications that indirectly led to alternative causes of death or morbidity. Moreover, given CVCs are associated with significant morbidity and cost \[[@B44]-[@B47]\], there should be concerted efforts to obtain alternative access in prevalent dialysis patients.

Conclusion
==========

In summary, an acute dialysis start is associated with increased mortality and exclusion of this population attenuates the mortality risk of CVC use. Prior registry reports may have overestimated CVC mortality, as acute starts were not considered. Additional studies should be conducted to further establish the potential modifying effect of an acute start on CVC associated mortality.
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